Page 18 - MGMG Jan-June 2020 Final

• Second, we bring two most important dimensions – deeper understanding of the patient and the
drug-disease behaviors to further understand every patient in complete detail and then determine
the optimal medical intervention for that patient.

• Third, our insights are delivered using precise individual scores (represented by survival and
adverse events) with a detailed explanation of how individual dimensions contributed towards the
score.

• Fourth, we learn. Our algorithms continuously take into account the real-time feed-back from
caregivers and improvise the scores on a regular basis.

• Finally, by leveraging cutting-edge capabilities of AI and computing, we analyze any bit of
relevant data (example: genetics, images, doctor notes, audio and videos, social media, healthcare
records, pathology etc.) for unparalleled insights about diseases, their networks and the impact of
interventions.

Our Product -- The “CIBIL” Equivalent of Healthcare!

• Suites of algorithms for detecting diseases and disease networks

• Deliver precise “Quant” Scores to indicate propensity

• Our algorithms leverage cutting edge computational capabilities to
understand disease networks at cellular and genetic levels

• We target all 3 key constituents of healthcare: Provider Payers
• Payers (commercial and government)
• Life Sciences including CROs Life
• Providers Sciences

Confidential Document ©Copyrights of CognitiveCare. 6 www.cognitivecare.com

Specific condition- Path results

16